linjc16/ctgov huggingface dataset:
Effect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to investigate the effect of the enteric hormone Glucagon-like Peptide (GLP-2) on patients with short bowel syndrome

Detailed Description
-----------------
previous studies have shown that GLP-2 increases mesenteric blow flow, we wish to examine the effect of subcutaneus GLP-2 on patients with short bowl syndrome. The patients will single blinded been given 450 nmol GLP-2 and isotonic saline in order to act as their own reference.

Official Title
-----------------
GLP-2 Mediated Increased SMA Blood Flow in Patients With Short Bowel Syndrome

Conditions
-----------------
Short Bowel Syndrome

Intervention / Treatment
-----------------
* Drug: GLP-2
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical diagnose of short bowel syndrome 4 month of stable fase Exclusion Criteria: activity in IBD

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: 2<br>subcutaneous isotonic saline | Drug: Placebo<br> <br> |
| Active Comparator: 1<br>subcutaneous GLP-2 | Drug: GLP-2<br>* 450 nmol subcutaneous<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
mesenteric blood flow, GLP-2, short bowel syndrome, Glucagon-Like Peptide 2
Pediatric Refraction With SVOne Autorefractor

Study Overview
=================
Brief Summary
-----------------
The study is used to verify the accuracy and repeatability of Smart Vision Labs Refractor in a pediatric population (between 5 and 16 years of age).

Official Title
-----------------
Pediatric Refraction With SVOne Autorefractor

Conditions
-----------------
Ocular Refraction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy children ages 5-16 year male and female Exclusion Criteria: presence of ocular disease refractive surgery amblyopia

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sphere refraction measurement | the outcome include sphere refraction (in diopter) measurements by using both Smart Vision Labs autorefractor and subjective refraction | up to 6 months | 
| Cylinder refraction measurement | the outcome include cylinder refraction (in diopter) measurements by using both Smart Vision Labs autorefractor and subjective refraction | up to 6 months | 
| difference between two Sphere refraction measurements on the same patient | the outcome include the difference (in diopter) between two Sphere refraction measurements on the same patient by using smart vision labs autorefractor | up to 6 months | 
| difference between two cylinder refraction measurements on the same patient | the outcome include the difference (in diopter) between two cylinder refraction measurements on the same patient by using smart vision labs autorefractor | up to 6 months |
Assessment of Activities of Daily Living in Adults With Chronic Low Back Pain Using a Nonoperative Treatment Modality

Study Overview
=================
Brief Summary
-----------------
The investigators hypothesize that treatment with non-invasive spinal decompression reduces discogenic low back pain (LBP), decreases visual analog pain scale scores, increases activities of daily living and decreases medication use.

Official Title
-----------------
Assessment of Activities of Daily Living in Adults With Chronic Low Back Pain Using a Nonoperative Treatment Modality: A Retrospective Study

Conditions
-----------------
Low Back Pain

Intervention / Treatment
-----------------
* Device: DRX9000


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: at least 18 years of age; consented to the physician prescribed protocol; presented with discogenic low back pain defined as low back pain for minimum of 12 weeks; current CT scan Exclusion Criteria: metastatic cancer; previous spinal fusion or placement of stabilization hardware within 6 months; instrumentation or artificial discs; neurologic motor deficits, bladder, or sexual dysfunction; alcohol or drug abuse patient's with extremes of height (< 147 cm or > 203 cm) and body weight (> 136 kg).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: DRX9000|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lower back pain measured on an 11-point numeric rating scale (VAS) with 0 reflecting no pain at all and 10 the worst imaginable pain. | 0= no pain; 10=worst pain | 12-16 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Functional capacity, measured by activities of daily living |  | 12-16 weeks | 
| Proportion of patients using adjuvant analgesic medication |  | 12-16 weeks |
Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy and safety of VI-0521 compared to placebo in the glycemic management of obese diabetic adults.

Official Title
-----------------
A Phase 2, Randomized, Double Blind, Parallel Design Study Comparing the Efficacy and Safety of VI-0521 to Placebo in the Glycemic Management of Obese Diabetic Adults

Conditions
-----------------
Type 2 Diabetes Mellitus

Intervention / Treatment
-----------------
* Drug: VI-0521
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Informed consent Type 2 Diabetes BMI 27-42 Specified diet/exercise and/or diabetes medications Exclusion Criteria: BP > 150/95 Stroke/MI/unstable cardiovascular disease within 6 months Clinically significant renal, hepatic, or psychiatric disease Unstable thyroid disease or replacement therapy Nephrolithiasis Obesity of known genetic or endocrine origin Participation in a formal weight loss program or lifestyle intervention History of glaucoma Pregnancy or breastfeeding Alcohol abuse Eating disorder Excluded medications

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Phentermine 15mg/topiramate 100mg | Drug: VI-0521<br>* phentermine 15mg/topiramate 100mg<br>|
| Placebo Comparator: 2<br>Matched placebo | Drug: Placebo<br>* matched placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change From Baseline in HbA1c at Week 28. |  | Baseline to 28 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Absolute Weight Change (kg) From Baseline to Week 28 |  | Baseline to 28 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetes, Obese diabetics
Management of a Giant Lymphocele Following Varicose Vein Surgery - A Case Report

Study Overview
=================
Brief Summary
-----------------
A 48-year-old female presented to the plastic surgery outpatient department (OPD) with a history of painful, progressive swelling of the right groin and medial aspect of the right thigh for 4 months. After investigation, it was diagnosed as a giant lymphocele. A pedicled gracilis muscle flap was used to reconstruct and obliterate the cavity. There was no recurrence of the swelling. : Lymphocele is a common complication after extensive vascular surgeries. In the unfortunately case of its development, prompt intervention must be done to prevent its growth and ensuing complications.

Official Title
-----------------
Management of a Giant Lymphocele Following Varicose Vein Surgery - A Case Report

Conditions
-----------------
Lymphocele, Varicose Veins

Intervention / Treatment
-----------------
* Procedure: Lymphocele excision and space obliterated by pedicle Gracilis muscle only flap


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosed case of lymphocele - Exclusion Criteria: none -
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Lymphocele excision and space obliterated by pedicle Gracilis muscle only flap|By this procedure it has helped in reduction and complete resolution of the lymphocele with no recurrence in the past 2 years|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Management of a Giant Lymphocele Following Varicose Vein Surgery - A Case Report | Complete resolution of lymphocele | 2 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lymphocele, Varicose Vein, Gracilis Muscle, Sclerotherapy.
Identification of an Atypical acetabuLar frActure With an Independent Roof Component: Incidence and Description

Study Overview
=================
Brief Summary
-----------------
Treatment of acetabular fractures needs a perfect diagnosis to anticipate surgical difficulties. E. Letournel described a rare atypical both-column fracture which  introduces enormous surgical difficulties . Its particularity is a sagittal comminution interesting the acetabular roof. In this experience the particular fracture is probably under-diagnosed. The purpose of this study is to give the exact incidence and a precise description of these fractures to improve their surgical management.

Official Title
-----------------
Identification of an Atypical acetabuLar frActure With an Independent Roof Component: Incidence and Description

Conditions
-----------------
Acetabular Fracture

Intervention / Treatment
-----------------
* Procedure: acetabular fracture surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient with acetabular fracture Exclusion Criteria: other type of fracture
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: acetabular fracture surgery|acetabular fracture surgery|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| measurement of volume-rendered 3D-CT images on preoperative CT-scans |  | Day 1 |
Low Salt Diet in Idiopathic Hypercalciuria

Study Overview
=================
Brief Summary
-----------------
Randomized clinical trial comparing water therapy plus low-salt diet to water therapy alone in patients affected by idiopathic calcium nephrolithiasis. Treatment duration: three months Primary end-point: correction of hypercalciuria Main inclusion criteria: calcium stone formers with idiopathic hypercalciuria, with at least one stone expelled and analyzed by infrared spectrophotometry; presence of hypercalciuria (>300 mg/day in males and >200 mg/day in females); 18-65 years. Main exclusion criteria: primary hyperparathyroidism, primary hyperoxaluria, enteric hyperoxaluria, bowel resection, inflammatory bowel disease, renal tubular acidosis, sarcoidosis, sponge kidney, hyperthyroidism, use of hypercalciuric drugs such as Vitamin D, acetazolamide, anti-epileptic drugs

Official Title
-----------------
Calcium Nephrolithiasis: Clinical Characteristics and Nutritional Determinants

Conditions
-----------------
Hypercalciuria

Intervention / Treatment
-----------------
* Behavioral: Low salt diet
* Behavioral: Water therapy alone


Participation Criteria
=================
Eligibility Criteria
-----------------
Main inclusion criteria: idiopathic calcium stone formers, with at least one stone expelled and analyzed by infrared spectrophotometry; presence of hypercalciuria (>300 mg/day in males and 20 mg/day in females); 18-65 years. Main exclusion criteria: primary hyperparathyroidism, primary hyperoxaluria, enteric hyperoxaluria, bowel resection, inflammatory bowel disease, renal tubular acidosis, sarcoidosis, sponge kidney, hyperthyroidism, use of hypercalciuric drugs such as Vitamin D, acetazolamide, anti-epileptic drugs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Low salt diet plus water therapy<br> | Behavioral: Low salt diet<br> <br> |
| Active Comparator: water therapy alone<br> | Behavioral: Water therapy alone<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Normalization of urinary calcium levels |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in urinary stone risk factors (e.g. urinary calcium, oxalate and sodium excretion); blood pressure reduction |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Low salt diet, idiopathic hypercalciuria, calcium stone formers, Calcium stone formers with idiopathic hypercalciuria
Molecular Characterization of Perivascular Epithelioid Cell Tumors

Study Overview
=================
Brief Summary
-----------------
Perivascular epithelioid cell tumors (PEComas) are rare and are characterized by the expression of myomelanocytic markers. They are a complex family that includes angiomyolipomas, lymphangioleiomyomatoses and other soft tissue and visceral tumors. Due to the low prevalence of these tumors, the natural history is unclear; furthermore, a molecular classification integrating clinical, pathological and molecular parameters has not been described to date.

Official Title
-----------------
Molecular Characterization of Perivascular Epithelioid Cell Tumors

Conditions
-----------------
Perivascular Epithelioid Cell Tumor, Malignant

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Major patient (≥18 years) Minor patient (1 to 17 years old) PEComas diagnosed in France between 01/01/1990 and 15/09/2019 and reviewed by a sarcoma referral pathologist Exclusion criteria : Opposition of the patient (or the holders of parental authority) to participate in the study Biological tissue from a patient who does not meet all the inclusion criteria Classic triphasic angiomyolipoma or lymphangioleiomyomatosis Inability to provide informed information to the subject Patient under court protection Patient under guardianship or curatorship

Ages Eligible for Study
-----------------
Minimum Age: 1 Year

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To retrospectively describe the percentage of tumors with FISH (Fluorescence In Situ Hybridization) identification of the TFE3 rearrangement out of 100 cases of PEComas diagnosed in France between 01 January 1990 and 15 September 2019 |  | Files analysed retrospectively from January 01, 1990 to September 15, 2019 will be examined | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Perivascular epithelioid cell tumors, PEComas, Myomelanocytic markers, Angiomyolipomas, Lymphangioleiomyomatoses, Visceral tumors, Fluorescence In Situ Hybridization
Trial Comparing Early Complications of Two Techniques in the Laparoscopic Gastric Bypass

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to define and evaluate the early complications between two different surgical techniques used to perform a laparoscopic gastric bypass

Official Title
-----------------
Prospective Randomized Trial Comparing Early Complications of Hand-Sewn Versus Circular Stapled Gastro-Jejunal Anastomosis in Laparoscopic Gastric Bypass

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Procedure: Laparoscopic Gastric Bypass
* Procedure: Laparoscopic Gastric Bypass


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Body mass Index between 35 with comorbidities and 50 kg/mt2 Exclusion Criteria: Body mass index <35kg7mt2 and >50kg/mt2

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Circular Stapled<br>Patients operated performing the gastric pouch of the gastric bypass with a circular staple device | Procedure: Laparoscopic Gastric Bypass<br> <br> |
| Active Comparator: Handsewn anastomosis<br>Patients operated performing the gastric pouch of the gastric bypass in a handsewn manner | Procedure: Laparoscopic Gastric Bypass<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Early Complications of both techniques, Fistula rate, Dehiscence rate, reoperation rate and cause
The Relation Between MiR-125b-5p and Staging of Endometriosis

Study Overview
=================
Brief Summary
-----------------
78 endometriosis patients presented with infertility were clinically examined and the diagnosis was assured by US imaging. The study also included 11 control fertile women free of gynecological problems as a control for lab tests. Patients and controls gave blood samples for lab investigations. All patients underwent diagnostic abdominal laparoscopy under general anesthesia for disease staging. Quantitative determination of expression levels of genes of microRNA-125b-5p and 203a was conducted using qRT-PCR.

Official Title
-----------------
Estimation of Plasma Levels of MicroRNA 125b-5p and Transvaginal Ultrasonography May Spare Laparoscopy for Staging of Endometriosis

Conditions
-----------------
Endometriosis

Intervention / Treatment
-----------------
* Procedure: laparoscopic examination
* Diagnostic Test: Blood sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who presented clinical pictures suggestive of EM disease Exclusion Criteria: Patients with previous pelvic or abdominal surgery that may hinder the laparoscopic examination, patients who were suspicious of having malignancy elsewhere in the body region, pregnant women, patients who had diabetes mellitus, body mass index (BMI) of >30 kg/m2, coagulopathies, and autoimmune disorders.

Ages Eligible for Study
-----------------
Minimum Age: 22 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Patients<br> | Procedure: laparoscopic examination<br>* laparoscopic examination for staging of endometriosis<br>|
| Active Comparator: Control<br> | Diagnostic Test: Blood sampling<br>* Blood sample to detect endometriosis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Validity of Plasma expression level | the diagnostic validity of estimation of plasma expression levels of MiR-125b-5p and 203a for diagnosis and staging of endometriosis. | two weeks |